SAPHO syndrome with bacillus Calmette-Guérin (BCG) immunotherapy for bladder cancer

BMJ Case Reports

Volumn , Issue , 2010, Pages

  Matsumaru, Katsuhiko ^a   Nagai, Kazuki ^a   Murakami, Takayuki ^b   Andoh, Kazuo ^c  

^a Nagai Clinic   (Japan)

^b Yokohama Minami Kyosai Hospital   (Japan)

^c Saiseikai Yokohama shi Nanbu Hosp   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84897586258     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr.12.2009.2591     Document Type: Article

References (12)

1. Chamot AM, Benhamou CL, Kahn MF, et al. [Acne-pustulosis-hyperostosis- osteitis syndrome. Results of a national survey. 85 cases]. Rev Rhum Mal Osteoartic 1987;54:187-96. [Medline]
2. Hayem G, Bouchaud-Chabot A, Benali K, et al. SAPHO syndrome: a long-term follow-up study of 120 cases. Semin Arthritis Rheum 2000;29:332-34. [CrossRef] [Medline] [Web of Science]
3. Kirchhoff T, Merkesdal S, Rosenthal H, et al. Diagnostic management of patients with SAPHO syndrome: use of MR imaging to guide bone biopsy at CT for microbiological and histological work-up. Eur Radiol 2003;13:2304-8. [CrossRef] [Medline] [Web of Science] (Pubitemid 37220365)
4. Just A, Adams S, Brinkmeier T, et al. Successful treatment of primary chronic osteomyelitis in SAPHO syndrome with bisphosphonates. J Dtsch Dermatol Ges 2008;6:657-60. [CrossRef] [Medline]
5. Moll C, Hernández MV, Cañete JD, et al. Ilium osteitis as the main manifestation of the SAPHO syndrome: response to infliximab therapy and review of the literature. Semin Arthritis Rheum 2008;37:299-306. [CrossRef] [Medline] [Web of Science] (Pubitemid 351389483)
6. Sabugo F, Liberman C, Niedmann JP, et al. Infliximab can induce a prolonged clinical remission and a decrease in thyroid hormonal requirements in a patient with SAPHO syndrome and hypothyroidism. Clin Rheumatol 2008;27:533-5. [CrossRef] [Medline] [Web of Science] (Pubitemid 351404307)
7. Galadari H, Bishop AG, Venna SS, et al. Synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome treated with a combination of isotretinoin and pamidronate. J Am Acad Dermatol 2009;61:123-5. [CrossRef] [Medline] [Web of Science]
8. Zaharoff DA, Hoffman BS, Hooper HB, et al. Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12. Cancer Res 2009;69:6192-9. [Abstract/FREE Full text]
9. Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol 2009;182:2195-203. [CrossRef] [Medline] [Web of Science]
10. Videira PA, Calais FM, Correia M, et al. Efficacy of bacille Calmette-Guérin immunotherapy predicted by expression of antigen-presenting molecules and chemokines. Urology 2009;74:944-50. [CrossRef] [Medline] [Web of Science]
11. Sagnak L, Ersoy H, Ozok U, et al. Predictive value of urinary interleukin-8 cutoff point for recurrences after transurethral resection plus induction bacillus Calmette-Guérin treatment in non-muscle-invasive bladder tumors. Clin Genitourin Cancer 2009;7:E16-23. [CrossRef] [Medline] [Web of Science]
12. Hurtado-Nedelec M, Chollet-Martin S, Nicaise-Roland P, et al. Characterization of the immune response in the synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome. Rheumatology (Oxford) 2008;47:1160-7. [Abstract/FREE Full text] (Pubitemid 352038220)